While ANXA1's protective role in osteolysis has been established,[20] this study is the first to define its functional association with LCN2high MDSCs in the IVDD, thereby reinforcing LCN2‐ANXA1 axis as a mechanistically coherent therapeutic target for disc degeneration. The gene discussed is LCN2; the disease is intervertebral disk degenerative disorder.